Top Stories
The deal with AlzeCure Pharma, worth potentially more than $1 billion, centres on the preclinical gamma-secretase modulator ACD680.
A Phase III study testing Trodelvy with Merck & Co.'s Keytruda in first-line lung cancer was discontinued, while the companies' oral once-weekly single-tablet treatment regimen for HIV succeeded in two trials.
The European Commission cleared a subcutaneous version of Sanofi's anti-CD38 mAb Sarclisa, while GNI Group bought Ayumi Pharmaceutical for about $280 million.
With Monday's raise, City plans to advance experimental Stargardt disease treatment CITY-RBP4, alongside an undisclosed programme, into the clinic this year.
The company said elecoglipron helped 90% of diabetes patients reach guideline A1c targets while producing meaningful weight loss.
Conference News
A single intratumoral injection resulted in no reported skeletal‑related events (SREs) or fracturesNo treatment‑emergent adverse events (AEs) or serious adverse events (SAEs)Cessation of tumor activit...
LONDON and BOSTON and BUDAPEST, Hungary, June 09, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage company developing off-the-shelf and personalized active cancer immunotherapies, today announced ...
Our data suggest that MS 001 may help achieve several of the field’s objectives simultaneously: greater fat-selective weight loss, preservation of muscle, and improved durability of response.”— Randal...
Novo Nordisk and Eli Lilly intensified competition in obesity drugs at the American Diabetes Association (ADA) Scientific Sessions, highlighting growing uptake of their GLP-1 weight-loss pills ahead o...
MALMÖ, SE / ACCESS Newswire / June 9, 2026 / Ascelia Pharma AB (publ)(STO:ACE) announces that Orviglance® data will be presented as an oral presentation today at the European Society of Gastrointestin...
